Give It Up for Gut Cancers - Why give up Sugar?
January 22, 2025
Increased sugar intake is a major contributing factor to rising obesity levels which research shows increase the risk of developing gut cancers including; oesophageal, stomach, liver and pancreatic cancer.The main cause of weight gain comes down to sugar intake, in fact, it ...
Give It Up for Gut Cancers - Why give up Booze?
January 22, 2025
One of the options for GIVE IT UP for Gut Cancers is to go booze-free. After Christmas and New Years, many of us are thinking about our alcohol consumption and this has been a popular choice for GIU 2025! Here's some food for thought:❌ Limiting alcohol consumption can help...
Lenvatinib Funded for Liver Cancer Patients from 1 December
November 8, 2024
Today Pharmac has confirmed that Lenvatinib (Lenvima) will be available from 1 December for eligible patients with advanced unresectable Hepatocellular Carcinoma.This is a very welcome but long-awaited step forward and the first-time liver cancer patients in Aotearoa will be...
Cetuximab funded for some bowel cancer patients from 1 November 2024
October 10, 2024
1 November Update: Cetuximab (Erbitux) is now funded for some bowel cancer patients. To find out more, check eligibility and download resources including questions to ask your medical team, visit the Erbitux website.GCF is delighted to see today’s announcement that C...
The Gut Cancer Foundation (GCF) has today provided feedback to Pharmac as part of their consultation process for funding the liver cancer treatment, lenvatinib (Lenvima). Lenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an ...
Access to Keytruda Widened from 1 October 2024.
September 10, 2024
The Gut Cancer Foundation is heartened to receive news of widened access of pembrolizumab (Keytruda) for microsatellite instability high or deficient mismatch repair (MSI-H/dMMR) colorectal cancer (CRC) patients. Pharmac has listened to clinici...
GCF Provides Feedback for the Consultation on Pharmac Proposal to Widen Access to Pembrolizumab for Colorectal Cancer.
August 15, 2024
Earlier this month, Pharmac called for feeback on their proposal to widen access to Pembrolizumab to treat microsatellite instability-high or deficient mismatch repair (MSI-H/dMMR) colorectal cancer.We and the community we represent welcome the proposal. For a patient g...
Update on Medicine Funding for Liver Cancer
August 15, 2024
The Gut Cancer Foundation has today written to Pharmac in response to news released on Friday August 9th that they have issued a Future Procurement Opportunity (FPO) for the cancer treatment bevacizumab.Aotearoa/New Zealand remains an outlier with no funded systemic options ...
Gut Cancer Foundation Welcomes News of Funded Immunotherapy for Colorectal Cancer Patients
July 5, 2024
The Gut Cancer Foundation is delighted by Pharmac’s announcement today that they are proposing to fund Pembrolizumab (Keytruda) for patients with microsatellite instability-high or deficient mismatch repair (MSI-H/dMMR) colorect...
New Treatments Funded for Gut Cancer Patients
June 25, 2024
Yesterday's announcement of $604 million investment over four years to fund up to 26 cancer treatments is fantastic news for New Zealanders living with cancer. We are very pleased to see that the announcement includes the fulfilment of a promise to fund 2 new cancer drugs fo...
Loading...
TAGS
Pancreatic Cancerclinical trialPanCan GalaPancreasresearchShine A LightauctionBig Purple Dinnerbowel cancercancer drugsCancer preventionCDH1Gastric Cancergut microbiomeHereditary Diffuse Gastric CancermedicinesmicrobiomePancare FoundationPancreatic Cancer Awareness MonthPatient Supportpharmacstomach cancerstomach cancer awarenessstomach cancer awareness weektreatment access
Loading...